X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs ABBOTT INDIA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD ABBOTT INDIA ORCHID PHARMA LTD/
ABBOTT INDIA
 
P/E (TTM) x -0.5 42.8 - View Chart
P/BV x 0.4 10.7 3.5% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ORCHID PHARMA LTD   ABBOTT INDIA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
ABBOTT INDIA
Mar-16
ORCHID PHARMA LTD/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1946,015 3.2%   
Low Rs353,707 0.9%   
Sales per share (Unadj.) Rs276.51,236.9 22.4%  
Earnings per share (Unadj.) Rs-79.2122.2 -64.8%  
Cash flow per share (Unadj.) Rs-43.5129.0 -33.7%  
Dividends per share (Unadj.) Rs035.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs53.9521.2 10.3%  
Shares outstanding (eoy) m70.4521.25 331.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.43.9 10.5%   
Avg P/E ratio x-1.439.8 -3.6%  
P/CF ratio (eoy) x-2.637.7 -7.0%  
Price / Book Value ratio x2.19.3 22.8%  
Dividend payout %028.6 0.0%   
Avg Mkt Cap Rs m8,067103,296 7.8%   
No. of employees `0002.83.0 94.7%   
Total wages/salary Rs m2,5273,370 75.0%   
Avg. sales/employee Rs Th6,956.18,891.8 78.2%   
Avg. wages/employee Rs Th902.51,140.0 79.2%   
Avg. net profit/employee Rs Th-1,993.0878.3 -226.9%   
INCOME DATA
Net Sales Rs m19,47726,284 74.1%  
Other income Rs m407504 80.7%   
Total revenues Rs m19,88426,789 74.2%   
Gross profit Rs m1,1033,665 30.1%  
Depreciation Rs m2,519144 1,744.6%   
Interest Rs m5,2278 64,528.4%   
Profit before tax Rs m-6,2364,017 -155.2%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,421 -8.8%   
Profit after tax Rs m-5,5802,596 -214.9%  
Gross profit margin %5.713.9 40.6%  
Effective tax rate %2.035.4 5.7%   
Net profit margin %-28.79.9 -290.1%  
BALANCE SHEET DATA
Current assets Rs m11,01414,446 76.2%   
Current liabilities Rs m32,0604,725 678.6%   
Net working cap to sales %-108.137.0 -292.2%  
Current ratio x0.33.1 11.2%  
Inventory Days Days9551 184.6%  
Debtors Days Days3420 171.6%  
Net fixed assets Rs m29,4401,113 2,645.3%   
Share capital Rs m705213 331.5%   
"Free" reserves Rs m2,04310,808 18.9%   
Net worth Rs m3,80011,076 34.3%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51016,241 286.4%  
Interest coverage x-0.2497.0 -0.0%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.41.6 25.9%   
Return on assets %-0.816.0 -4.7%  
Return on equity %-146.923.4 -626.5%  
Return on capital %-3.736.3 -10.3%  
Exports to sales %37.90.6 6,160.9%   
Imports to sales %22.612.6 179.0%   
Exports (fob) Rs m7,378162 4,565.3%   
Imports (cif) Rs m4,4063,322 132.6%   
Fx inflow Rs m7,513268 2,803.5%   
Fx outflow Rs m5,6493,927 143.8%   
Net fx Rs m1,865-3,659 -51.0%   
CASH FLOW
From Operations Rs m1,6822,514 66.9%  
From Investments Rs m-9,860-800 1,233.3%  
From Financial Activity Rs m6,644-803 -827.5%  
Net Cashflow Rs m-1,535912 -168.3%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.6 7.9 58.2%  
FIIs % 3.3 0.1 3,300.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.1 323.4%  
Shareholders   84,811 18,270 464.2%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS